BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Wadman RI, van der Pol WL, Bosboom WM, Asselman FL, van den Berg LH, Iannaccone ST, Vrancken AF. Drug treatment for spinal muscular atrophy types II and III. Cochrane Database Syst Rev. 2020;1:CD006282. [PMID: 32006461 DOI: 10.1002/14651858.cd006282.pub5] [Cited by in Crossref: 12] [Cited by in F6Publishing: 16] [Article Influence: 6.0] [Reference Citation Analysis]
Number Citing Articles
1 Shin HJ, Na J, Lee H, Lee Y. Nusinersen for spinal muscular atrophy types II and III: a retrospective single-center study in South Korea. World J Pediatr 2022. [DOI: 10.1007/s12519-022-00638-x] [Reference Citation Analysis]
2 Kryuchkova TA, Balakireva EA. Spinal muscular atrophy type 2: efficacy of risdiplam in a 7-year-old child. Ross vestn perinatol pediatr 2022;67:100-106. [DOI: 10.21508/1027-4065-2022-67-3-100-106] [Reference Citation Analysis]
3 Cumplido-Trasmonte C, Ramos-Rojas J, Delgado-Castillejo E, Garcés-Castellote E, Puyuelo-Quintana G, Destarac-Eguizabal MA, Barquín-Santos E, Plaza-Flores A, Hernández-Melero M, Gutiérrez-Ayala A, Martínez-Moreno M, García-Armada E. Effects of ATLAS 2030 gait exoskeleton on strength and range of motion in children with spinal muscular atrophy II: a case series. J Neuroeng Rehabil 2022;19:75. [PMID: 35854321 DOI: 10.1186/s12984-022-01055-x] [Reference Citation Analysis]
4 Aslesh T, Yokota T. Restoring SMN Expression: An Overview of the Therapeutic Developments for the Treatment of Spinal Muscular Atrophy. Cells 2022;11:417. [PMID: 35159227 DOI: 10.3390/cells11030417] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
5 Stępień A, Gajewska E, Rekowski W. Motor Function of Children with SMA1 and SMA2 Depends on the Neck and Trunk Muscle Strength, Deformation of the Spine, and the Range of Motion in the Limb Joints. Int J Environ Res Public Health 2021;18:9134. [PMID: 34501722 DOI: 10.3390/ijerph18179134] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
6 Krosschell KJ, Townsend EL, Kiefer M, Simeone SD, Zumpf K, Welty L, Swoboda KJ. Natural history of 10-meter walk/run test performance in spinal muscular atrophy: A longitudinal analysis. Neuromuscular Disorders 2021. [DOI: 10.1016/j.nmd.2021.08.010] [Reference Citation Analysis]
7 Behera B. Nusinersen, an exon 7 inclusion drug for spinal muscular atrophy: A minireview. World J Meta-Anal 2021; 9(3): 277-285 [DOI: 10.13105/wjma.v9.i3.277] [Reference Citation Analysis]
8 Butterfield RJ. Spinal Muscular Atrophy Treatments, Newborn Screening, and the Creation of a Neurogenetics Urgency. Semin Pediatr Neurol 2021;38:100899. [PMID: 34183144 DOI: 10.1016/j.spen.2021.100899] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
9 Freigang M, Wurster CD, Hagenacker T, Stolte B, Weiler M, Kamm C, Schreiber-Katz O, Osmanovic A, Petri S, Kowski A, Meyer T, Koch JC, Cordts I, Deschauer M, Lingor P, Aust E, Petzold D, Ludolph AC, Falkenburger B, Hermann A, Günther R. Serum creatine kinase and creatinine in adult spinal muscular atrophy under nusinersen treatment. Ann Clin Transl Neurol 2021;8:1049-63. [PMID: 33792208 DOI: 10.1002/acn3.51340] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 11.0] [Reference Citation Analysis]
10 Ojala KS, Reedich EJ, DiDonato CJ, Meriney SD. In Search of a Cure: The Development of Therapeutics to Alter the Progression of Spinal Muscular Atrophy. Brain Sci 2021;11:194. [PMID: 33562482 DOI: 10.3390/brainsci11020194] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 9.0] [Reference Citation Analysis]
11 Menduti G, Rasà DM, Stanga S, Boido M. Drug Screening and Drug Repositioning as Promising Therapeutic Approaches for Spinal Muscular Atrophy Treatment. Front Pharmacol 2020;11:592234. [PMID: 33281605 DOI: 10.3389/fphar.2020.592234] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
12 Belter L, Jarecki J, Reyna SP, Cruz R, Jones CC, Schroth M, O'Toole CM, O'Brien S, Hall SA, Johnson NB, Paradis AD. The Cure SMA Membership Surveys: Highlights of Key Demographic and Clinical Characteristics of Individuals with Spinal Muscular Atrophy. J Neuromuscul Dis 2021;8:109-23. [PMID: 33104036 DOI: 10.3233/JND-200563] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
13 Messina S, Sframeli M. New Treatments in Spinal Muscular Atrophy: Positive Results and New Challenges. J Clin Med 2020;9:E2222. [PMID: 32668756 DOI: 10.3390/jcm9072222] [Cited by in Crossref: 55] [Cited by in F6Publishing: 59] [Article Influence: 27.5] [Reference Citation Analysis]
14 Chen TH. New and Developing Therapies in Spinal Muscular Atrophy: From Genotype to Phenotype to Treatment and Where Do We Stand? Int J Mol Sci. 2020;21. [PMID: 32392694 DOI: 10.3390/ijms21093297] [Cited by in Crossref: 34] [Cited by in F6Publishing: 37] [Article Influence: 17.0] [Reference Citation Analysis]
15 Wadman RI, van der Pol WL, Bosboom WM, Asselman FL, van den Berg LH, Iannaccone ST, Vrancken AF. Drug treatment for spinal muscular atrophy type I. Cochrane Database Syst Rev 2019;12:CD006281. [PMID: 31825542 DOI: 10.1002/14651858.CD006281.pub5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]